iron metabolism

By Targets:	Ferroportin (1) Bacterial (2) Biochemical Assay Reagents (1) Endogenous Metabolite (2) Fluorescent Dye (1) TGF-beta/Smad (1)
By Research Areas:	Infection (2) Metabolic Disease (5)

Targets Recommended: Mitochondrial Metabolism Ferroportin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

HY-147379

Hepcidin antagonist-1	Others	Metabolic Disease
Hepcidin antagonist-1 (example 104) is a potent hepcidin (hepcidine) antagonist with an IC₅₀<50 μM. Hepcidin antagonist-1 can be used for researching iron metabolism disorders, such as anemias .

HY-135024

Phenylacetyl CoA Phenylacetyl Coenzyme A	Endogenous Metabolite	Metabolic Disease
Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

HY-135024A

Phenylacetyl CoA lithium Phenylacetyl Coenzyme A lithium	Endogenous Metabolite	Metabolic Disease
Phenylacetyl CoA lithium (Phenylacetyl Coenzyme A lithium) is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

HY-157433

Mab-SaS-IN-1	Bacterial	Infection
Mab-SaS-IN-1 (compoud 1H) is Mab-SaS inhibitor with the IC₅₀ of 2 μM. Mab-SaS-IN-1 can be used for study of antibiosis by blocking iron uptake and metabolism .

HY-145965

Ferroportin-IN-1	Ferroportin	Metabolic Disease
Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .

HY-149353

Antibacterial agent 145	Bacterial	Infection
Antibacterial agent 145 (compound 1b) is an antibacterial agent depending on bacterial iron uptake pathway. Antibacterial agent 145 disrupts cytoplasmic membrane integrity and inhibits cell metabolism but exhibits low cytotoxic effects to normal cells .

HY-D1533

RhoNox-1 1 Publications Verification	Fluorescent Dye	Others
RhoNox-1 is a fluorescent probe for the specific detection of divalent iron ions, and when RhoNox-1 reacts with Fe ²⁺. RhoNox-1 can generate an irreversible orange (red) fluorescent product (Ex/Em：540/575 nm) . FeRhoNox-1 can enter the cell well, suitable for the detection of Fe ²⁺ in living cells, and tends to be localized in the Golgi apparatus .

HY-W088066

Trisodium phosphate dodecahydrate Phosphoric acid, sodium salt, hydrate (1:3:12)	Biochemical Assay Reagents	Others
Trisodium phosphate dodecahydrate is a corrosion inhibitor for iron in 0.1 M NaClO4, in both aerated and deaerated solutions. Trisodium phosphate dodecahydrate can be used as an excipient, such as pH regulator, buffer. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

Cat. No.	Product Name

HY-L133

Cuproptosis Compound Library	187 compounds
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis". The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis. Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism. Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis. MCE supplies a unique collection of 187 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cuproptosis Compound Library

187 compounds

Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".

The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.

Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.

Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.

MCE supplies a unique collection of 187 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cat. No.	Product Name	Type

HY-D1533

RhoNox-1 1 Publications Verification	Fluorescent Dyes/Probes
RhoNox-1 is a fluorescent probe for the specific detection of divalent iron ions, and when RhoNox-1 reacts with Fe ²⁺. RhoNox-1 can generate an irreversible orange (red) fluorescent product (Ex/Em：540/575 nm) . FeRhoNox-1 can enter the cell well, suitable for the detection of Fe ²⁺ in living cells, and tends to be localized in the Golgi apparatus .

Cat. No.	Product Name	Target	Research Area

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-135024

Phenylacetyl CoA Phenylacetyl Coenzyme A	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

HY-135024A

Phenylacetyl CoA lithium Phenylacetyl Coenzyme A lithium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Phenylacetyl CoA lithium (Phenylacetyl Coenzyme A lithium) is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Inhibitory Antibodies

Natural
Products